Telaprevir or boceprevir triple therapy in patients with chronic hepatitis C and varying severity of cirrhosis
Alimentary Pharmacology & Therapeutics2014Vol. 39(10), pp. 1213–1224
Citations Over TimeTop 10% of 2014 papers
Varun Saxena, M. Michele Manos, Helen S. Yee, Lisa Catalli, Elizabeth M. Wayne, Robert C. Murphy, Valentina Shvachko, Mary Patricia Pauly, Joel V. Chua, Alexander Monto, Norah A. Terrault
Abstract
In the presence of mild decompensation (Child-Pugh ≥6), SVR12 rates with protease inhibitor triple therapy are significantly reduced and adverse events increased. Thus, treatment with protease inhibitor triple therapy, if judged as necessary, should be undertaken with close monitoring and awareness of the significant risks.
Related Papers
- → UK consensus guidelines for the use of the protease inhibitors boceprevir and telaprevir in genotype 1 chronic hepatitis C infected patients(2012)89 cited
- → Peg-interferon plus ribavirin with or without boceprevir or telaprevir for HCV genotype 1: A meta-analysis on role of response predictors(2014)2 cited
- → Boceprevir and telaprevir: new treatments for chronic hepatitis C(2012)1 cited
- → PIN58 Cost Per Sustained Virological Response of Telaprevir and Boceprevir in the Treatment of Genotype 1 Hepatitis C Patients According to the Previous Treatment Response and the Metavir Groups in Brazil(2012)1 cited
- → Treatment patterns, health care resource utilization and costs in united states patients diagnosed with chronic hepatitis c infection(2014)